BeiGene
BGNE
#934
Rank
NZ$35.98 B
Marketcap
$323.48
Share price
-2.10%
Change (1 day)
-0.77%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

P/S ratio for BeiGene (BGNE)

P/S ratio as of November 2024 (TTM): 6.75

According to BeiGene 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.21. At the end of 2024 the company had a P/S ratio of 4.93.

P/S ratio history for BeiGene from 2016 to 2024

PS ratio at the end of each year

Year P/S ratio Change
20244.93-38.81%
20238.06-51.36%
202216.6-29.1%
202123.4-69.96%
202077.8223.81%
201924.0-42.86%
201842.0125.23%
201718.7-98.34%
2016> 1000

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
92.5 1,269.99%๐Ÿ‡บ๐Ÿ‡ธ USA
1.56-76.92%๐Ÿ‡บ๐Ÿ‡ธ USA